ABP 692 is an investigational medication being studied for its effects on relapsing-remitting multiple sclerosis. It is being compared to an existing treatment to see if it works in a similar way in the body and has similar effects on the disease.

Ocrevus® (Ocrelizumab) is a medication already approved for the treatment of relapsing-remitting multiple sclerosis. It works by targeting specific cells in the immune system to reduce inflammation and prevent new brain lesions, which are common in multiple sclerosis. This study is comparing the effects of ABP 692 to Ocrevus® to ensure they are similar in terms of how they work and their safety profiles.

Relapsing-remitting Multiple Sclerosis – This is a form of multiple sclerosis characterized by episodes of new or increasing neurological symptoms, known as relapses, followed by periods of partial or complete recovery. During a relapse, individuals may experience symptoms such as vision problems, muscle weakness, or coordination difficulties. These symptoms can vary in severity and duration. After a relapse, there is a remission phase where symptoms may improve or disappear entirely. However, over time, some symptoms may persist and accumulate, leading to gradual disability. The disease course is unpredictable, with the frequency and severity of relapses varying among individuals.